Insider Buying: Braveheart Bio (NASDAQ:BRVE) Director Acquires 1,940,000 Shares

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Orbimed Advisors Llc acquired 1,940,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the purchase, the director directly owned 11,901,826 shares of the company’s stock, valued at approximately $214,232,868. This represents a 19.47% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Braveheart Bio Price Performance

BRVE traded down $2.52 during mid-day trading on Tuesday, hitting $25.01. 724,651 shares of the stock were exchanged, compared to its average volume of 569,084. Braveheart Bio, Inc. has a 1-year low of $24.61 and a 1-year high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.